Ignore the MC from 3 years ago as the MC shouldn't have been that high. You need to determine what you think the MC is worth after the next 3 years of IP development, HER-Vaxx (completed Ph2 clinical trial with very good result released early 2024), PD1-Vaxx (commenced Ph2 clinical trial end of 2023 so IMU saw enough data from Ph1 clinical trial in the last 3 years), VAXINIA (initial clinical trial update was excellent so received Fast Track designation and ODD from the FDA), OASIS (still waiting for initial clinical trial update but LC has mentioned it's going as expected similar to what she said about VAXINIA before the release) and Azer-Cel (acquire for blood cancer market but also CD19 and clinical trial update was excellent). I think the MC should be worth $750M-$1B with over $106M in cash and potentially $50M in R&D rebate, you????
IMU Price at posting:
4.3¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)